Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials

BACKGROUND. The prognostic significance of baseline contrast enhancing tumor prior to second- or third-line therapy in recurrent glioblastoma (GBM) for overall survival (OS) remains controversial, particularly in the context of repeated surgical resection and/or use of anti-angiogenic therapy. In th...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Main Authors: Ellingson, Benjamin M., Harris, Robert J., Woodworth, Davis C., Leu, Kevin, Zaw, Okkar, Mason, Warren P., Sahebjam, Solmaz, Abrey, Lauren E., Aftab, Dana T., Schwab, Gisela M., Hessel, Colin, Lai, Albert, Nghiemphu, Phioanh L., Pope, Whitney B., Wen, Patrick Y., Cloughesy, Timothy F.
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2017
Assuntos:
Clinical Investigations
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5193027/
https://ncbi.nlm.nih.gov/pubmed/27580889
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now187
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares